The biological significance of soluble interleukin-2 receptors in solid tumors-Reference-Cited by-同舟云学术

The biological significance of soluble interleukin-2 receptors in solid tumors

Published:1990-01 Issue:1 Volume:26 Page:33-36
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Lissoni P.,Barni S.,Rovelli F.,Viviani S.,Maestroni G.J.M.,Conti A.,Tancini G.

Publisher

Elsevier BV

Subject

Oncology

Reference8 articles.

1. Immunoincompetence in cancer patients;Dillman,1984

2. Decreased TCGF activity in the culture medium, of PHA stimulated peripheral mononuclear cells from patients with metastatic cancer;Nakayama;Clin Exp Immunol,1983

3. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma;Mitchell;J Clin Oncol,1988

4. Soluble interleukin 2 receptors are released by activated human lymphoid cells in vitro;Rubin;J Immunol,1985

5. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival;Wagner;J Clin Oncol,1987

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients;Investigational New Drugs;2023-04-14

2. High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma;Surgery;2020-10

3. Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer;Pathologica;2019-06

4. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients;PLOS ONE;2015-07-20

5. Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects;Clinical Lymphoma Myeloma and Leukemia;2015-06